Aurobindo Pharma shares in focus after Telangana API facility gets two observations from US FDA

Aurobindo Pharma shares will remain in focus after the US FDA completed an inspection of its Unit-V facility, with two procedural observations. The company will respond within the stipulated time. In Q2 FY25, Aurobindo Pharma reported an 8.6% YoY rise in net profit to Rs 817 crore and an 8% increase in revenue to Rs 7,796 crore.